Is COLL or COYA more undervalued in 2026?

CirclFi compares Collegium Pharmaceutical, Inc. (COLL) and Coya Therapeutics, Inc. (COYA) using 13 institutional-grade valuation models. COLL has a Quality of Company score of 9.2/10 while COYA scores 5.5/10.

Which is a better buy — COLL or COYA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do COLL and COYA valuations compare?

COLL at $33.61 and COYA at $4.82 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

COLL vs COYA Valuation Comparison 2026 — Intrinsic Value Analysis

COLL

Pharmaceutical Preparations

Collegium Pharmaceutical, Inc.

Quality

9.2

out of 10

Value Trap

SAFE

Price

$33.61

Last close

Models

12/13

Active

COYA

Pharmaceutical Preparations

Coya Therapeutics, Inc.

Quality

5.5

out of 10

Value Trap

LOW

Price

$4.82

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	COLL Fair Value	COLL Upside	COYA Fair Value	COYA Upside
Bayesian DCF	Intrinsic	$138.44	+311.9%	$2.39	-50.4%
Earnings Power Value	Intrinsic	$30.34	-9.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$27.80	-17.3%	$0.11	-97.5%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for COLL vs COYA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

COLL vs COYA — Which Stock Is More Undervalued?

COLL scores higher with a 9.2/10 quality rating vs COYA's 5.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Collegium Pharmaceutical, Inc. (COLL) and Coya Therapeutics, Inc. (COYA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

COLL currently trades at $33.61 with a QOC of 9.2/10, while COYA trades at $4.82 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).